Replies to post #7674 on PharmaCyte Biotech Inc (PMCB)

[DITRstocks]

Nuvilex, through its soon-to-be acquired assets of SG Austria, has designed and utilized in clinical trials, a proprietary multi-functional, biomedical therapeutic enhancement platform. This platform, which essentially serves as an existing therapy booster, is based upon its live-cell encapsulation technology and delivery system and enhances the quality of life.

$NVLX

[Cool_Trades]

The Celgene trial has garnered attention but there are other treatments under development that have not only garnered significant attention, but provide great valuation comparables for Nuvilex which strongly supports our valuation thesis.

$NVLX